Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
AUSTRALIA held their nerve with the ball to secure a seventh successive final appearance in the Women’s T20 World Cup with a tense five-run victory over India in their semi-final at Newlands in Cape Town on Thursday (23).
Australia won the toss and elected to bat, posting a par score of 172 for four, before restricting India to 167 for eight in reply. They will now await the winner of Friday’s second semi-final between England and hosts South Africa.
Australia’s total came thanks to a 37-ball 54 from opener Beth Mooney and an excellent 49 not out from 34 balls by captain Meg Lanning.
Lanning and Ash Gardner (31 from 18 balls) gave the innings important impetus towards the back end as they put on 53 in six overs to propel Australia to what proved a winning score.
"That is one of the best wins I've been involved in, to fight back after not playing our best cricket in all three facets," Lanning said at the post-match presentation.
"India came hard at us, so we knew this score would be hard to defend. But we pulled through in the clutch moments.
"I think we are able to stay calm and composed, we didn't panic even when we weren't bowling well. These are the kind of games we want to win."
India were always up with the required run rate, but lost regular wickets until Jemimah Rodrigues (43 from 24 balls) and captain Harmanpreet Kaur (52 from 34 balls) put on 69 for the fourth wicket to put their side in the driving seat.
But they were struck a blow when Kaur was run out in bizarre circumstances in a turning point in the game as her bat got caught in the wicket as she tried to slide it in and she ended up short of the line in what had appeared an easy run.
India went into the final over needing 16 runs to win, but spinner Gardner (2-37) bowled Australia to victory with an excellent all-round performance.
"We got the momentum back (with the bat). To lose from there, we weren't expecting this. The way I got run out, you can't be unluckier than that," Kaur said.
"We again gave some easy catches away. When you have to win, you have to take your chances. We can only learn from this."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.